Home/ Stocks/ REGN

Regeneron Pharmaceuticals Inc

REGN XNAS

$741.69 +0.00 (+0.00%) ▲ 15-min delayed

Open

N/A

High

N/A

Low

N/A

Volume

N/A

Market Cap

$77.87B

About Regeneron Pharmaceuticals Inc

Regeneron Pharmaceuticals discovers, develops, and commercializes products that fight eye disease, cardiovascular disease, cancer, and inflammation. The company has several marketed products, including low-dose Eylea and Eylea HD, approved for wet age-related macular degeneration and other eye diseases; Dupixent in immunology; Praluent for LDL cholesterol lowering; Libtayo in oncology; and Kevzara in rheumatoid arthritis. Regeneron is also developing monoclonal and bispecific antibodies with Sanofi, other collaborators, and independently, and has early-stage partnerships that bring new technology to the pipeline, including RNAi (Alnylam) and Crispr-based gene editing (Intellia).

Sector: PHARMACEUTICAL PREPARATIONS Employees: 15.4K Website →

Key Financials

Period	Revenue	Net Income	EPS
TTM 2025	$14.34B	$4.50B	$43.07
FY 2025	$14.34B	$4.50B	$43.07
Q3 2025	$3.75B	$1.46B	$14.09
Q2 2025	$3.68B	$1.39B	$13.24

TickerDaily Coverage

Why Are Top Stocks Up Big Before the Bell Friday? Pre-Market Movers March 20, 2026

Market News Sarah Mitchell · 4d ago

Three major stocks are ripping higher in pre-market trading Friday, March 20, 2026, ahead of the...

Why Are Top Stocks Moving Before the Bell Today? Pre-Market Movers March 18

Market News Sarah Mitchell · 6d ago

Five major stocks are making significant pre-market moves on Wednesday, March 18, 2026, ahead of...

Top Stocks Moving Pre-Market Today: NVDA, LLY, AMD Pre-Market Movers Before the Bell

Market News Sarah Mitchell · Mar 6, 2026

Several major stocks are posting outsized pre-market moves ahead of today's opening bell, driven by...

View All Coverage →

Get REGN Alerts

Stay ahead with breaking news, price alerts, and expert analysis on Regeneron Pharmaceuticals Inc.

Disclaimer: This page is for informational purposes only. Stock data is delayed by at least 15 minutes. Always conduct your own research and consult with a qualified financial advisor before making investment decisions.